Current Medicinal Chemistry

This journal supports open access

Editor-in-Chief:

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK

Back

Become EABM
Become Reviewer



Meet Our Editorial Board Member free to download

Volume:26   Issue: 9
Pp: 1507-1508
Doris Mangiaracina Benbrook
DOI: 10.2174/092986732609190521112612



The Role of Modified and Dysfunctional Lipoproteins in Atherogenesis free to download

Volume:26   Issue: 9
Pp: 1509-1511
Alexander N. Orekhov
DOI: 10.2174/092986732609190521112756



Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?

Volume:26   Issue: 9
Pp: 1512-1524
Alexander N. Orekhov* and Igor A. Sobenin
DOI: 10.2174/0929867325666180320121137



Lipoproteins in Atherosclerosis Process

Volume:26   Issue: 9
Pp: 1525-1543
Valentina Arnao, Antonino Tuttolomondo*, Mario Daidone and Antonio Pinto
DOI: 10.2174/0929867326666190516103953



HDL Dysfunction Caused by Mutations in apoA-I and Other Genes that are Critical for HDL Biogenesis and Remodeling

Volume:26   Issue: 9
Pp: 1544-1575
Angeliki Chroni* and Dimitris Kardassis*
DOI: 10.2174/0929867325666180313114950



The Significance of Oxidized Low-Density Lipoprotein in Body Fluids as a Marker Related to Diseased Conditions

Volume:26   Issue: 9
Pp: 1576-1593
Hiroyuki Itabe*, Rina Kato, Naoko Sawada, Takashi Obama and Matsuo Yamamoto
DOI: 10.2174/0929867325666180307114855



The Role of (Modified) Lipoproteins in Vascular Function: A Duet Between Monocytes and the Endothelium

Volume:26   Issue: 9
Pp: 1594-1609
Johan G. Schnitzler, Geesje M. Dallinga-Thie* and Jeffrey Kroon*
DOI: 10.2174/0929867325666180316121015



Dysfunctional HDL as a Therapeutic Target for Atherosclerosis Prevention

Volume:26   Issue: 9
Pp: 1610-1630
Alice Ossoli, Chiara Pavanello, Eleonora Giorgio, Laura Calabresi and Monica Gomaraschi*
DOI: 10.2174/0929867325666180316115726



Impact of Dysfunctional Protein Catabolism on Macrophage Cholesterol Handling

Volume:26   Issue: 9
Pp: 1631-1643
Takuro Miyazaki* and Akira Miyazaki
DOI: 10.2174/0929867325666180326165234



Biological Consequences of Dysfunctional HDL

Volume:26   Issue: 9
Pp: 1644-1664
Angela Pirillo *, Alberico Luigi Catapano* and Giuseppe Danilo Norata
DOI: 10.2174/0929867325666180530110543



Electronegative LDL: An Active Player in Atherogenesis or a By- Product of Atherosclerosis?

Volume:26   Issue: 9
Pp: 1665-1679
Andrea Rivas-Urbina, Anna Rull, Jordi Ordóñez-Llanos and José Luis Sánchez-Quesada*
DOI: 10.2174/0929867325666180330093953



Modified LDL Immune Complexes and Cardiovascular Disease

Volume:26   Issue: 9
Pp: 1680-1692
Maria F. Lopes-Virella and Gabriel Virella*
DOI: 10.2174/0929867325666180524114429



Role of Ox-LDL and LOX-1 in Atherogenesis

Volume:26   Issue: 9
Pp: 1693-1700
Ajoe John Kattoor, Sri Harsha Kanuri and Jawahar L. Mehta*
DOI: 10.2174/0929867325666180508100950



Triglyceride-Rich Lipoproteins as a Source of Proinflammatory Lipids in the Arterial Wall

Volume:26   Issue: 9
Pp: 1701-1710
Katariina Öörni*, Satu Lehti, Peter Sjövall and Petri T. Kovanen
DOI: 10.2174/0929867325666180530094819